143 related articles for article (PubMed ID: 36606295)
1. An intensive longitudinal examination of topiramate treatment for alcohol use disorder: a secondary analysis of data from a randomized controlled trial.
Votaw VR; Witkiewitz K; Van Horn ML; Crist RC; Pond T; Kranzler HR
Addiction; 2023 Jun; 118(6):1040-1052. PubMed ID: 36606295
[TBL] [Abstract][Full Text] [Related]
2. GRIK1 genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink.
Kranzler HR; Armeli S; Feinn R; Tennen H; Gelernter J; Covault J
Int J Neuropsychopharmacol; 2014 Oct; 17(10):1549-56. PubMed ID: 24786948
[TBL] [Abstract][Full Text] [Related]
3. GRIK1 genotype and daily expectations of alcohol's positive effects moderate the reduction of heavy drinking by topiramate.
Kranzler HR; Armeli S; Tennen H; Gelernter J; Covault J
Exp Clin Psychopharmacol; 2014 Dec; 22(6):494-501. PubMed ID: 25436841
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder.
Kranzler HR; Morris PE; Pond T; Crist RC; Kampman KM; Hartwell EE; Lynch KG
Neuropsychopharmacology; 2021 Jul; 46(8):1407-1413. PubMed ID: 33568796
[TBL] [Abstract][Full Text] [Related]
5. Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.
Morley KC; Kranzler HR; Luquin N; Jamshidi N; Adams C; Montebello M; Tremonti C; Dali G; Logge W; Baillie A; Teesson M; Trent R; Haber PS
Am J Psychiatry; 2024 May; 181(5):403-411. PubMed ID: 38706338
[TBL] [Abstract][Full Text] [Related]
6. Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder.
Kranzler HR; Hartwell EE; Feinn R; Pond T; Witkiewitz K; Gelernter J; Crist RC
Drug Alcohol Depend; 2021 Aug; 225():108762. PubMed ID: 34049101
[TBL] [Abstract][Full Text] [Related]
7. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study).
Morley KC; Kranzler HR; Luquin N; Baillie A; Shanahan M; Trent R; Teesson M; Haber PS
Trials; 2018 Aug; 19(1):443. PubMed ID: 30115121
[TBL] [Abstract][Full Text] [Related]
8. Post-treatment effects of topiramate on alcohol-related outcomes: A combined analysis of two placebo-controlled trials.
Kranzler HR; Feinn R; Pond T; Hartwell E; Gelernter J; Crist RC; Witkiewitz K
Addict Biol; 2022 Mar; 27(2):e13130. PubMed ID: 35229945
[TBL] [Abstract][Full Text] [Related]
9. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism.
Kranzler HR; Covault J; Feinn R; Armeli S; Tennen H; Arias AJ; Gelernter J; Pond T; Oncken C; Kampman KM
Am J Psychiatry; 2014 Apr; 171(4):445-52. PubMed ID: 24525690
[TBL] [Abstract][Full Text] [Related]
10. Self-efficacy mediates the effects of topiramate and GRIK1 genotype on drinking.
Kranzler HR; Armeli S; Wetherill R; Feinn R; Tennen H; Gelernter J; Covault J; Pond T
Addict Biol; 2016 Mar; 21(2):450-9. PubMed ID: 25496338
[TBL] [Abstract][Full Text] [Related]
11. Posttreatment effects of topiramate treatment for heavy drinking.
Kranzler HR; Wetherill R; Feinn R; Pond T; Gelernter J; Covault J
Alcohol Clin Exp Res; 2014 Dec; 38(12):3017-23. PubMed ID: 25581656
[TBL] [Abstract][Full Text] [Related]
12. Balancing risk and benefit in heavy drinkers treated with topiramate: implications for personalized care.
Feinn R; Curtis B; Kranzler HR
J Clin Psychiatry; 2016 Mar; 77(3):e278-82. PubMed ID: 26891181
[TBL] [Abstract][Full Text] [Related]
13. Topiramate's reduction of body mass index in heavy drinkers: lack of moderation by a GRIK1 polymorphism.
Kranzler HR; Feinn R; Gelernter J; Pond T; Covault J
Exp Clin Psychopharmacol; 2014 Oct; 22(5):419-23. PubMed ID: 24978347
[TBL] [Abstract][Full Text] [Related]
14. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial.
Johnson BA; Ait-Daoud N; Akhtar FZ; Ma JZ
Arch Gen Psychiatry; 2004 Sep; 61(9):905-12. PubMed ID: 15351769
[TBL] [Abstract][Full Text] [Related]
15. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment.
Kranzler HR; Armeli S; Covault J; Tennen H
Addict Biol; 2013 Jan; 18(1):193-201. PubMed ID: 22784013
[TBL] [Abstract][Full Text] [Related]
16. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study.
Miranda R; MacKillop J; Monti PM; Rohsenow DJ; Tidey J; Gwaltney C; Swift R; Ray L; McGeary J
Alcohol Clin Exp Res; 2008 Mar; 32(3):489-97. PubMed ID: 18215213
[TBL] [Abstract][Full Text] [Related]
17. Topiramate treatment for alcoholic outpatients recently receiving residential treatment programs: a 12-week, randomized, placebo-controlled trial.
Likhitsathian S; Uttawichai K; Booncharoen H; Wittayanookulluk A; Angkurawaranon C; Srisurapanont M
Drug Alcohol Depend; 2013 Dec; 133(2):440-6. PubMed ID: 23906999
[TBL] [Abstract][Full Text] [Related]
18. Molecular Correlates of Topiramate and GRIK1 rs2832407 Genotype in Pluripotent Stem Cell-Derived Neural Cultures.
Lieberman R; Jensen KP; Clinton K; Levine ES; Kranzler HR; Covault J
Alcohol Clin Exp Res; 2020 Aug; 44(8):1561-1570. PubMed ID: 32574382
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
Falk DE; O'Malley SS; Witkiewitz K; Anton RF; Litten RZ; Slater M; Kranzler HR; Mann KF; Hasin DS; Johnson B; Meulien D; Ryan M; Fertig J;
JAMA Psychiatry; 2019 Apr; 76(4):374-381. PubMed ID: 30865232
[TBL] [Abstract][Full Text] [Related]
20. Biobehavioral mechanisms of topiramate's effects on alcohol use: an investigation pairing laboratory and ecological momentary assessments.
Miranda R; MacKillop J; Treloar H; Blanchard A; Tidey JW; Swift RM; Chun T; Rohsenow DJ; Monti PM
Addict Biol; 2016 Jan; 21(1):171-82. PubMed ID: 25353306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
